Dr. Nina Rawal is a venture capital investor and strategic advisor with 25 years of experience spanning science, venture investing, industry, and consulting. She is the founder of emerging health ventures, an advisory platform advancing life science innovation for underserved patients, and serves on the investment committee of We Venture Capital. Previously, she co-led Trill Impact Ventures, a $100 million life science fund, and headed life science investments at Industrifonden. Earlier roles include VP Strategy and Ventures at Gambro and consultant at Boston Consulting Group in Stockholm and New York. A World Economic Forum Young Global Leader, she works with investors, companies, and institutions globally. She holds a PhD in Molecular Neurobiology and an MSc in Biomedicine from Karolinska Institutet, with research conducted at Columbia University and Hôpital de la Salpêtrière.
The European Union's agreement to pay a 15% tariff on pharmaceutical exports to the United States, breaking a 30-year commitment to zero tariffs on medicines, is the latest signal that th...
Descuidar la salud de las mujeres tiene un costo enorme, tanto en sufrimiento humano como en potencial económico perdido.
Neglecting women’s health comes at a staggering cost, in human suffering and lost economic potential.
我们进入了新冠肺炎大流行的第二年，世界上绝大多数地区都迫切需要获得能够让生活恢复至正常水平的疫苗。疫苗的快速开发可能是整个大流行中最激发信心的事情——疫苗的平均开发时间已经从5-10年缩短到不到1年。尽管开发时间短，但这些疫苗的功效很强，堪称科学奇迹。然而，国家内部的疫苗分发以及国家之间的疫苗分发，就远谈不上奇迹了。
As we move into a second year of the COVID-19 pandemic, an overwhelming part of the world desperately awaits access to vaccines that hold the power to return life to a version of normal. ...
As we move further into the COVID-19 pandemic it is becoming increasingly clear that many of the tools and measures deployed by high-income countries against the virus are most probably n...
